Desvenlafaxine Succinate
Generic Name: desvenlafaxine succinate
Brand Names:
Desvenlafaxine Succinate
Desvenlafaxine is an extended-release tablet for oral administration that contains desvenlafaxine succinate, a structurally novel SNRI for the treatment of MDD.
Overview
Desvenlafaxine is an extended-release tablet for oral administration that contains desvenlafaxine succinate, a structurally novel SNRI for the treatment of MDD.
Uses
Desvenlafaxine extended-release tablet is indicated for the treatment of adults with major depressive disorder (MDD). The medication functions as a serotonin and norepinephrine reuptake inhibitor.
Dosage
Recommended dosage is 50 mg once daily with or without food. Higher doses provide no additional benefit. The 25 mg dose is intended for gradual dose reduction during discontinuation. Tablets must be swallowed whole and not divided or crushed.
Side Effects
Most common reactions include nausea, dizziness, insomnia, hyperhidrosis, constipation, somnolence, decreased appetite, anxiety, and specific male sexual function disorders.
Interactions
Significant interactions include MAOIs (contraindicated), other serotonergic drugs, antiplatelet/anticoagulant medications, and CYP2D6-metabolized drugs requiring potential dose adjustment.
Warnings
Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults. Not approved for pediatric use. Serotonin syndrome risk, elevated blood pressure requiring monitoring, increased bleeding risk, angle closure glaucoma, mania activation, and discontinuation syndrome risks. Contraindicated with hypersensitivity to desvenlafaxine or venlafaxine and MAOI use.
Pregnancy
Exposure to SNRIs, particularly in the month before delivery, has been associated with a less than 2-fold increase in the risk of postpartum hemorrhage. Third-trimester exposure may cause neonatal discontinuation syndrome.
Frequently Asked Questions
What is Desvenlafaxine Succinate used for?▼
Desvenlafaxine extended-release tablet is indicated for the treatment of adults with major depressive disorder (MDD). The medication functions as a serotonin and norepinephrine reuptake inhibitor.
What are the side effects of Desvenlafaxine Succinate?▼
Most common reactions include nausea, dizziness, insomnia, hyperhidrosis, constipation, somnolence, decreased appetite, anxiety, and specific male sexual function disorders.
Can I take Desvenlafaxine Succinate during pregnancy?▼
Exposure to SNRIs, particularly in the month before delivery, has been associated with a less than 2-fold increase in the risk of postpartum hemorrhage. Third-trimester exposure may cause neonatal discontinuation syndrome.
What are the important warnings for Desvenlafaxine Succinate?▼
Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults. Not approved for pediatric use. Serotonin syndrome risk, elevated blood pressure requiring monitoring, increased bleeding risk, angle closure glaucoma, mania activation, and discontinuation syndrome risks. Contraindicated with hypersensitivity to desvenlafaxine or venlafaxine and MAOI use.
Related Medications
Diphenhydramine Hydrochloride 50mg
diphenhydramine hydrochloride 50mg
Use For relief of occasional sleeplessness for relied of occasional sleeplessness
Motixafortide
motixafortide
11 DESCRIPTION APHEXDA for injection contains motixafortide, which is a hematopoietic stem cell mobilizer. The chemical name of the synthetic motixafortide acetate, the active pharmaceutical ingredient, is N-(4-Fluoro-benzoyl)-L-arginyl-L-arginyl-[L-3-naphthyl)alanyl]-L-cysteinyl-L-tyrosyl 5 -L-citrullinyl-L-lysyl-D-lysyl-L-prolyl-L-tyrosyl 10 -L-arginyl-L-citrullinyl-L-cysteinyl-L-arginineamide, cyclic (4-13)-disulfide, acetate salt.
Melaleuca Quinquenervia
melaleuca quinquenervia
Dosage form: SOLUTION. Route: INTRADERMAL, PERCUTANEOUS, SUBCUTANEOUS. Active ingredients: MELALEUCA QUINQUENERVIA POLLEN (.05 g/mL). Category: BLA.
Medical Disclaimer
This drug information is for educational purposes only and should not replace professional medical advice. Drug information is sourced from the FDA National Drug Code Directory and Structured Product Labeling. Always consult with a healthcare provider before starting, stopping, or changing any medication.